Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Public Sector Pension Investment Board

Key Points

• Public Sector Pension Investment Board increased its stake in Regeneron Pharmaceuticals by 9.5%, owning 14,055 shares worth approximately $8.91 million.
• The stock has seen a change in ratings from various analysts, with an average rating of "Moderate Buy" and a consensus target price of $838.00.
• Regeneron reported strong quarterly earnings with an EPS of $12.89, significantly exceeding the expected $8.43, alongside a revenue increase of 3.6% year-over-year.

Public Sector Pension Investment Board raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 9.5% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 14,055 shares of the biopharmaceutical company's stock after purchasing an additional 1,217 shares during the period. Public Sector Pension Investment Board's holdings in Regeneron Pharmaceuticals were worth $8,914,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Adirondack Trust Co. boosted its stake in shares of Regeneron Pharmaceuticals by 4.2% in the first quarter. Adirondack Trust Co. now owns 451 shares of the biopharmaceutical company's stock worth $286,000 after buying an additional 18 shares during the last quarter. Kingswood Wealth Advisors LLC boosted its stake in shares of Regeneron Pharmaceuticals by 1.8% in the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock worth $681,000 after buying an additional 19 shares during the last quarter. Creative Financial Designs Inc. ADV boosted its stake in shares of Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock worth $139,000 after buying an additional 19 shares during the last quarter. Private Trust Co. NA boosted its stake in shares of Regeneron Pharmaceuticals by 13.1% in the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after buying an additional 19 shares during the last quarter. Finally, Proficio Capital Partners LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.2% in the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after buying an additional 19 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $14.44 during mid-day trading on Friday, reaching $580.41. 1,121,578 shares of the stock traded hands, compared to its average volume of 985,857. The business has a 50-day moving average of $544.21 and a 200 day moving average of $594.90. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,211.20. The stock has a market capitalization of $61.52 billion, a PE ratio of 14.63, a PEG ratio of 1.93 and a beta of 0.33. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, beating analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%. The business had revenue of $3,675,600 billion during the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter in the prior year, the firm earned $11.56 earnings per share. The business's revenue was up 3.6% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Monday, August 18th will be issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on REGN shares. Morgan Stanley restated an "overweight" rating and issued a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Guggenheim upped their price target on Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Royal Bank Of Canada upped their price target on Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a report on Monday, August 4th. JPMorgan Chase & Co. reduced their price target on Regeneron Pharmaceuticals from $950.00 to $800.00 and set an "overweight" rating for the company in a report on Monday, June 9th. Finally, Redburn Atlantic raised Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have given a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $838.00.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.